Alexander Ciurej
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alexander Ciurej has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Avanti Gupte
Pediatric Department, Children’s Hospital of Michigan, Detroit, MI 48201, USA
1 shared publication - Elizabeth C. Lewis
School of Medicine, Wayne State University, Detroit, MI 48201, USA
1 shared publication - Eman Al-Antary
Children's Hospital of Michigan
1 shared publication
Latest Publications
- Open Access
Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
Immune checkpoint inhibitors (ICIs) are a relatively new class of immunotherapy which bolsters the host immune system by “turning off the brakes” of effector cells (e.g., CTLA-4, PD-1, PD-L1). Although their success in treating adult malignancy is well documented, their utility in pediatric cancer has not yet been shown to be as fruitful. We review ICIs, their use in pediatric malignancies, and active pediatric clinical trials, exemplifying some of adult efforts that could be related to pediatric future trials and complications of ICI therapy. Through our review, we propose the consideration of ICI as standard therapy in lymphoma and various solid tumor types, especially in relapsed or refractory (R/R) disease. However, further studies are needed to demonstrate ICI effectiveness in pediatric leukemia.
Open AccessCheckpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?
Immune checkpoint inhibitors (ICIs) are a relatively new class of immunotherapy which bolsters the host immune system by “turning off the brakes” of effector cells (e.g., CTLA-4, PD-1, PD-L1). Although their success in treating adult malignancy is well documented, their utility in pediatric cancer has not yet been shown to be as fruitful. We review ICIs, their use in pediatric malignancies, and active pediatric clinical trials, exemplifying some of adult efforts that could be related to pediatric future trials and complications of ICI therapy. Through our review, we propose the consideration of ICI as standard therapy in lymphoma and various solid tumor types, especially in relapsed or refractory (R/R) disease. However, further studies are needed to demonstrate ICI effectiveness in pediatric leukemia.